Literature DB >> 35718846

Stroke admissions during the COVID-19 pandemic: a single-center retrospective analysis.

Marina Padroni1, Michele Laudisi2, Cristiano Azzini3, Alesandro De Vito3, Ilaria Casetta2.   

Abstract

BACKGROUND AND AIMS: The SARS-CoV-2 pandemic affected the organization of the healthcare system, and several studies analyzed the impact on hospitalization for non-COVID diseases, in particular during the first wave period. We sought to analyze the impact of the pandemic on stroke care in the province of Ferrara during a longer pandemic period and its different phases.
METHODS: We retrospectively analyzed data of all patients with acute ischemic stroke admitted to the University Hospital of Ferrara from March 2020 to April 2021. Data were compared with nonpandemic reference periods (RP, March-April 2018 and 2019).
RESULTS: We observed a 31% reduction in monthly admission rate for ischemic stroke (IRR 0.69; 95% CI 0.51-0.94) and monthly thrombolysis rate (IRR 0.3; 95% CI 0.15-0.66) during the first-COVID-wave (March-April 2020), as compared to RP. A nonsignificant difference was recorded for admission rate when comparing RP with subsequent pandemic phases, but the thrombolysis rate was confirmed reduced. A significant increase in onset to door time (OTD) was observed in the CP-I period (median 230 vs 120 in the RP; p < 0.05) with improvement in the subsequent phases but without returning to baseline. Nonsignificant differences in the thrombectomy rates were found over the study period.
CONCLUSION: These findings reflect changing patient attitudes during the COVID-19 pandemic or the success of health system and public health campaigns to reassure patients about the safety of seeking emergency care when needed, not only for more severe stroke symptoms.
© 2022. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Admission rate; COVID pandemic; Stroke; Stroke treatment

Mesh:

Year:  2022        PMID: 35718846      PMCID: PMC9206880          DOI: 10.1007/s10072-022-06207-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


Introduction

During the SARS-CoV-2 pandemic, concerns have arisen regarding patient access and delivery of acute stroke (as well as other time-dependent diseases) care, due diversion of resources, conflicting demands on emergency care utilization, stay-at-home order, and social distancing. Several studies have reported a decline in stroke admissions, delay in hospital arrival, and, as a result, reduction of acute therapeutic procedures, in many countries, including Italy during the first wave of the pandemic [1-6]. Little is known about the hospitalization trend during later pandemic stages. We sought to analyze the impact of SARS-CoV-2 on stroke care in the province of Ferrara, northeastern Italy, over the course of the pandemic, from March 2020 to April 2021.

Methods

The study was conducted in the province of Ferrara, northeastern Italy. The population of the study area was 346,563 inhabitants, 179,968 women and 166,595 men. The Ferrara University Hospital is the major hospital and the only comprehensive stroke center of the study area. Other small hospitals provide outpatient neurological services, but lack neurological and neurosurgical divisions, so that according to our acute stroke pathway, all stroke patients are directly referred to our hospital. This mothership model remained unchanged over the study period. The pathway for acute stroke treatment was fully maintained, without any restriction in the capacity and personnel of the Stroke Unit/Neurological ward. Contingency plans to contain the pandemic were implemented beginning from the end of February 2020. The national lockdown was started on March 8 and removed on June 3. Since the beginning of the fall, a second epidemic wave took place: Italy rode out its second wave using a three-tiered system of localized restrictions on movements, leading to a partial, transient reduction in transmission. The vaccination campaign began on 27 December 2020. More than 1 year after the start of the pandemic, Italy experienced a new lockdown since mid-March 2021, due to a third wave of SARS-CoV-2 infections. Our hospital arranged ad hoc measures to avoid viral spread within the hospital including a pre-triage to identify suspected/confirmed SARS-CoV-2 infections and channel them into a dedicated pathway, separated from unsuspected patients /non-COVID-19 patients. Resources for acute stroke care were not restricted. We reviewed data of all patients with ischemic stroke (ICD code 433.*, 434.*) admitted to the hospital during the period March–April 2020 (COVID-19 period–first wave–CP-I). The same months in 2018 and 2019 were considered as reference period (RP). To evaluate the trend of admission rates during the entire pandemic, we collected also data regarding the months August–September 2020 (post-lockdown period (PLP)), October–November 2020 (COVID-19 period–second wave–CP-II), and March April 2021 (COVID-19 period–third wave–CP-III). The study was approved by the Local Ethics Committee.

Statistical analysis

We calculated the monthly rate per 100,000 of hospital admission during the reference and the COVID-19 periods, and the incidence rate ratio (IRR) with the use of Poisson regression. Other data were presented as absolute numbers, percentages, mean ± standard deviation (SD) or median and interquartile ranges (IQR) as appropriate on the basis of data distribution. Comparative analysis of clinical data were performed between the RP, the first and third waves of COVID-19. Comparison between continuous variables was performed using a two-tailed, independent samples Student t-test or Mann–Whitney U test. Dichotomous variables were compared using the chi-squared test.

Results

A total of 164 ischemic stroke patients were admitted to hospital, with a mean monthly admission rate of 11.8 per 100,000 in the RP. During the CP-I, we registered 57 admission for ischemic stroke giving an average admission rate of 8.2 per 100,000. Compared to the RP, we observed a 31% reduction in hospitalization for ischemic stroke (IRR 0.69; 95% CI 0.51–0.94). The decline in admission rate was similar in the two genders (IRR 0.69–95% CI 0.44–1.09 for men, and 0.69–95% CI 0.46–1.04) for women. In the post-lockdown period, the mean admission rate increased to 10.7 per 100,000 (95% CI 8.8–12.9) nonsignificantly lower than that recorded in the RP (IRR 0.9 per 100,000; 95% CI 0.7–1.15). During the second wave of the pandemic, we estimated a mean monthly admission rate of 10.8 per 100,000 (95% CI 8.5–13.5) giving a IRR of 0.92 (95% CI 0.7–1.2) as compared to the RP. The monthly admission rate in the course of the third wave was 12.1 per 100,000 (95% CI 9.6–15). The results are summarized in Table 1.
Table 1

Monthly admission rates during RP, CP-I, PLP, CP-II, and CP-III

No. of casesMonthly admission rate (95% CI)Rate ratio (95% CI)
Reference period (March–April 2018–2019)16411.8 (10.09–13.8)Reference
COVID-I wave period578.2 (6.2–10.7)0.69 (0.51–0.94)
Post-lockdown period (July–September 2020)11110.7 (8.8–12.9)0.9 (0.71–1.15)
COVID-II wave (October–November 2020)7510.8 (8.5–13.5)0.92 (0.7–1.2)
COVID-III wave (March–April 2021)8412.1 (9.6–15)1.02 (0.79–1.33)

p value < 0.05 Monthly admission rate CP-I vs RP

Monthly admission rates during RP, CP-I, PLP, CP-II, and CP-III p value < 0.05 Monthly admission rate CP-I vs RP The monthly intravenous thrombolysis (IVT) rate (Table 2) decreased from 3.68 per 100,000 (95% CI 2.7–4.8) in the RP to 1.15 (95% CI 0.5–2.3) in the CP-I with an IRR of 0.3 (95% CI 0.15–0.66). The same rate increased in the post-lockdown period but remained significantly lower (− 43%) as compared to the RP (IRR 0.57; 95% CI 0.35–0.95). During the RP, the proportion of stroke patients treated with IVT was 31%, and it significantly declined to 14% during the CP-I. The most frequent reason not to administer IVT was delayed hospital arrival. The fall in thrombolysis rates accounts for the reduced proportion of patients who underwent combined treatment (Table 2) during the pandemic. We confirmed the decline of the monthly IVT rate, as well as of the proportion of IVT-treated patients during the two subsequent infection waves (Table 2). The thrombectomy rates and the proportion of admitted patients treated with thrombectomy were substantially stable during the study period (Table 2).
Table 2

Thrombolysis and thrombectomy for ischemic stroke during RP, CP-I, PLP, CP-II, and CP-III

No. of casesProportion of patients treated with IVT (%)P valueMonthly thrombolysis rate (95% CI)Rate ratio (95% CI)Proportion of patients treated with EVT (%)P valueMonthly thrombectomy rate (95% CI)Rate ratio (95% CI)Proportion of EVT patients pretreated with IVT (%)P value
Reference period (March–April 2018–2019)16431.1Reference3.68 (2.7–4.8)Reference11Reference1.37 (0.85–2.1)Reference61.1Reference
COVID-I wave period5714.0 < 0.051.15 (0.5–2.2)0.31 (0.15–0.66)15.8 < 0.011.00 (0.45–2.2)0.74 (0.3–1.7)11.1 < 0.05
Post-lockdown period (July–September 2020)11119.8 < 0.052.12 (1.36–3.15)0.57 (0.35–0.95)12.60.681.35 (0.77–2.21)1.04 (0.52–2.1)42.80.3
COVID-II wave (October–November 2020)7521.30.122.31 (1.37–3.67)0.63 (0.36–1.10)14.70.071.59 (0.83–2.76)1.22 (0.58–2.59)27.30.07
COVID-III wave (March–April 2021)8415.5% < 0.051.88 (1.04–3.13)0.510 (0.28–0.94)10.70.951.3 (0.63–2.38)1.0 (0.45–2.23)22.20.055

p value < 0.005 Monthly thrombolysis rate CP-I vs RP

p value < 0.05 Monthly thrombolysis rate post-lockdown period vs RP, CP-II vs RP

EVT endovascular thrombectomy, IVT intravenous thrombolysis

Thrombolysis and thrombectomy for ischemic stroke during RP, CP-I, PLP, CP-II, and CP-III p value < 0.005 Monthly thrombolysis rate CP-I vs RP p value < 0.05 Monthly thrombolysis rate post-lockdown period vs RP, CP-II vs RP EVT endovascular thrombectomy, IVT intravenous thrombolysis We made a comparison of clinical data between RP, CP-I, and CP-III (Table 3).
Table 3

Clinical data and comparison between RP, CP-I, and CP-III

Reference period (4 months)COVID-I period (2 months)COVID-III period (2 months)
p value*p value**
No1645784
Age (mean, SD)75.7, 12.673.3,14.9n.s76.4, 12.1n.s
Baseline NIHSS (median, IQR)5, 3–116, 4–11.5n.s4.5, 2–10.5n.s
Onset to door (median, IQR)120 (74.5–190)230 (79–600) < 0.05190 (85–824) < 0.05
Call to scene time14 (11–18.75)16 (12–19)n.s16.4 (12.1–19.9)n.s
Scene to hospital arrival time38.7 (29.3–50.3)39.3 (30–52)n.s39.1 (30.6–51.8)n.s
Door to needle (median, IQR)60 (49–76.5)76 (59.5–124) < 0.0580 (59.5–134.5) < 0.05
Door to groin (median, IQR)99 (64.5–119.5)125 (75–136.5) < 0.0190 (60–111.2)n.s

*Comparisons between RP and CP-I

**Comparisons between RP and CP-III

Clinical data and comparison between RP, CP-I, and CP-III *Comparisons between RP and CP-I **Comparisons between RP and CP-III No significant differences in mean age at presentation, and stroke severity at onset were detected, although there was a nonsignificant trend toward a younger age as well as a lower severity of stroke at presentation during the CP-I. A significant increase in onset to door time (OTD) was observed in the CP-I period (median 230 vs 120 in the RP; p < 0.05); OTD improved in subsequent phases without returning to baseline figures. There were otherwise no significant differences in the ambulance call to scene arrival time and in the median ambulance scene arrival to hospital arrival time. Moreover, we observed a significant increase in door to needle time with a median delay of about 20 min compared to the RP. The onset to groin puncture time during the CP-I was significantly longer than in the RP, with a subsequent return to baseline values.

Discussion

One major concern related to the first COVID-19 wave was its negative effect on acute stroke care, with significant reduction of admission rates, IVT rates, and an impairment of workflow metrics. The impact of the pandemic on stroke admissions has been reported by multiple studies across countries with different COVID-19 burden. Despite SARS-CoV-2 infection could in itself be associated with an increased risk of cerebrovascular events [1], many studies detected a significant decline in hospitalization due to stroke during the pandemic period [2-7]. A national investigation showed a significant reduction in hospital admission and in thrombolysis rates across Italy [4]. In our study, the COVID-19 pandemic reduced the stroke admissions during the CP1 by a third and strongly affected the ODT and the quality of in-hospital care metrics. As a result, while endovascular treatments remained unchanged, we observed a significant decline in thrombolysis rates compared to before the pandemic due to reduced or delayed admission of stroke patients. These results were in accordance with a cross-sectional, observational, retrospective study across 6 continents [5]. The most likely interpretation of these findings is that stroke patients were not seeking emergency care or adopted a wait-and-see behavior, mainly due to fear of contagion and safety concerns, or nonrecognition of symptoms by isolated or older patients during the first lockdown period. According to a mothership model, in our area, the stroke pathway remained unchanged during the COVID-19 pandemic with prehospital notification of stroke cases to the neurologist and direct transfer of the patient to our hospital. An overload of emergency ambulance services did not seem to account for a lengthening in stroke-onset-to-hospital arrival time, since the ambulance response time did not increase over the pandemic. Thus, the lack of prompt activation of the emergency services remains the dominant obstacle in the prehospital phase of the stroke chain of survival. The substantial stability of the thrombectomy rates indirectly indicates that patients with more severe symptoms did not modify their health-seeking attitude. These findings are in agreement with other studies [4, 8–10], even if some reports showed a significant reduction also in endovascular procedures [11-13]. There were significant variations across and within countries reflecting differences in the sociocultural behaviors and healthcare organization [11]. Another study carried out in Italy [14] showed that during all the COVID-19 pandemic, despite a global reduction in the emergency department accesses, there was only a nonsignificant decrease in admissions for ischemic stroke and the rate of reperfusion therapies remain unchanged, but with longer onset to door time. In our study, the admission rate fell during the first wave, and returned to normality after the relaxing of the restriction measures where has remained ever since. Stroke physicians have been increasingly implementing information campaigns, encouraging patients to present early to the emergency room. It remains unclear whether the appeals of the scientific community during the first wave would have lessened the effect of any subsequent social containment mandates on stroke admissions. Nevertheless, a Greek study reported a persistent decline in hospitalization for acute stroke during the second wave of the COVID-19 pandemic [15]. The magnitude of reduction in admissions in the above study was similar to that of the first lockdown, suggesting that, regardless of the impact that COVID-19 has had on our community, social distancing mandates, restrictive measures and fear of infection have a negative impact on cerebrovascular diseases. In agreement with our findings, a nationwide Danish study showed that hospital admission rates returned to baseline levels during the post-lockdown phase of gradual reopening [16], even if with a transient drop during the second lockdown [17]. No significant declines in stroke alerts were observed during the largest second and third COVID-19 cases surge in Northern California [18]. On the contrary, in a severely COVID-affected area of Germany, there was a significant drop in total number of stroke patients presented during the second wave as compared to the first wave of the pandemic [19]. However, a nationwide study in the same country documented a smaller decline in hospitalizations for stroke during the second more severe wave than during the first one [20]. After all, in a state-wide analysis covering all types of acute cerebrovascular diseases in Austria [21], hospital admissions for TIA and ICH were reduced during and after the first wave of the COVID-19 pandemic while hospitalizations and recanalization treatments for IS were not affected in these two periods. The discrepancies in findings across different areas could be dependent on the degrees of severity of the infection rates. However, the impact of COVID pandemic in noninfectious acute diseases has proven to be independent from the local incidence of SARS-CoV-2 infection. More likely, transcultural differences in health-seeking behaviors and in reaction to sustained pandemic-related challenge played a role. The avoidance of seeking healthcare may not be driven directly by lockdowns per se but may be dependent on factors such as fear of the virus, not wanting to a further burden to hospital staff or fearing restrictions leading to further isolation from family members in hospitals. This, in conjunction with other variables (in particular the presence of a bystander at the onset of symptoms) could have influenced the prehospital notification and so the activation of the rescue chain [22]. The main limitation of the study is the small sample size due to the monocentric nature of this investigation. However, the study covers a relatively long observational period—including the first three waves of the COVID-19 pandemic—allowing to follow the changing patient attitudes, partly due to the success of public health campaigns encouraging patients to seek emergency care when needed. The decline in acute stroke admission rates during societal pandemic lockdowns is avoidable, and public health efforts to improve the collateral damage of potential future waves of COVID-19 pandemic is warranted. The impact of the pandemic on cerebrovascular diseases may be seen in the months and years to come.
  21 in total

1.  Stroke epidemiology and COVID-19 pandemic.

Authors:  Giancarlo Logroscino; Ettore Beghi
Journal:  Curr Opin Neurol       Date:  2020-12-04       Impact factor: 5.710

2.  The Curious Case of the Missing Strokes During the COVID-19 Pandemic.

Authors:  Diana Aguiar de Sousa; Else Charlotte Sandset; Mitchell S V Elkind
Journal:  Stroke       Date:  2020-05-29       Impact factor: 7.914

3.  Global Impact of COVID-19 on Stroke Care and IV Thrombolysis.

Authors:  Raul G Nogueira; Muhammad M Qureshi; Mohamad Abdalkader; Sheila Ouriques Martins; Hiroshi Yamagami; Zhongming Qiu; Ossama Yassin Mansour; Anvitha Sathya; Anna Czlonkowska; Georgios Tsivgoulis; Diana Aguiar de Sousa; Jelle Demeestere; Robert Mikulik; Peter Vanacker; James E Siegler; Janika Kõrv; Jose Biller; Conrad W Liang; Navdeep S Sangha; Alicia M Zha; Alexandra L Czap; Christine Anne Holmstedt; Tanya N Turan; George Ntaios; Konark Malhotra; Ashis Tayal; Aaron Loochtan; Annamarei Ranta; Eva A Mistry; Anne W Alexandrov; David Y Huang; Shadi Yaghi; Eytan Raz; Sunil A Sheth; Mahmoud H Mohammaden; Michael Frankel; Eric Guemekane Bila Lamou; Hany M Aref; Ahmed Elbassiouny; Farouk Hassan; Tarek Menecie; Wessam Mustafa; Hossam M Shokri; Tamer Roushdy; Fred S Sarfo; Tolulope Oyetunde Alabi; Babawale Arabambi; Ernest O Nwazor; Taofiki Ajao Sunmonu; Kolawole Wahab; Joseph Yaria; Haytham Hussein Mohammed; Philip B Adebayo; Anis D Riahi; Samia Ben Sassi; Lenon Gwaunza; Gift Wilson Ngwende; David Sahakyan; Aminur Rahman; Zhibing Ai; Fanghui Bai; Zhenhui Duan; Yonggang Hao; Wenguo Huang; Guangwen Li; Wei Li; Ganzhe Liu; Jun Luo; Xianjin Shang; Yi Sui; Ling Tian; Hongbin Wen; Bo Wu; Yuying Yan; Zhengzhou Yuan; Hao Zhang; Jun Zhang; Wenlong Zhao; Wenjie Zi; Thomas W Leung; Chandril Chugh; Vikram Huded; Bindu Menon; Jeyaraj Durai Pandian; P N Sylaja; Fritz Sumantri Usman; Mehdi Farhoudi; Elyar Sadeghi Hokmabadi; Anat Horev; Anna Reznik; Rotem Sivan Hoffmann; Nobuyuki Ohara; Nobuyuki Sakai; Daisuke Watanabe; Ryoo Yamamoto; Ryosuke Doijiri; Naoki Tokuda; Takehiro Yamada; Tadashi Terasaki; Yukako Yazawa; Takeshi Uwatoko; Tomohisa Dembo; Hisao Shimizu; Yuri Sugiura; Fumio Miyashita; Hiroki Fukuda; Kosuke Miyake; Junsuke Shimbo; Yusuke Sugimura; Yoshiki Yagita; Yohei Takenobu; Yuji Matsumaru; Satoshi Yamada; Ryuhei Kono; Takuya Kanamaru; Hidekazu Yamazaki; Manabu Sakaguchi; Kenichi Todo; Nobuaki Yamamoto; Kazutaka Sonoda; Tomoko Yoshida; Hiroyuki Hashimoto; Ichiro Nakahara; Aida Kondybayeva; Kamila Faizullina; Saltanat Kamenova; Murat Zhanuzakov; Jang-Hyun Baek; Yangha Hwang; Jin Soo Lee; Si Baek Lee; Jusun Moon; Hyungjong Park; Jung Hwa Seo; Kwon-Duk Seo; Sung Il Sohn; Chang Jun Young; Rechdi Ahdab; Wan Asyraf Wan Zaidi; Zariah Abdul Aziz; Hamidon Bin Basri; Law Wan Chung; Aznita Binti Ibrahim; Khairul Azmi Ibrahim; Irene Looi; Wee Yong Tan; Nafisah Wan Yahya; Stanislav Groppa; Pavel Leahu; Amal M Al Hashmi; Yahia Zakaria Imam; Naveed Akhtar; Maria Carissa Pineda-Franks; Christian Oliver Co; Dmitriy Kandyba; Adel Alhazzani; Hosam Al-Jehani; Carol Huilian Tham; Marlie Jane Mamauag; Narayanaswamy Venketasubramanian; Chih-Hao Chen; Sung-Chun Tang; Anchalee Churojana; Esref Akil; Özlem Aykaç; Atilla Ozcan Ozdemir; Semih Giray; Syed Irteza Hussain; Seby John; Huynh Le Vu; Anh Duc Tran; Huy Hoang Nguyen; Thong Nhu Pham; Thang Huy Nguyen; Trung Quoc Nguyen; Thomas Gattringer; Christian Enzinger; Monika Killer-Oberpfalzer; Flavio Bellante; Sofie De Blauwe; Geert Vanhooren; Sylvie De Raedt; Anne Dusart; Robin Lemmens; Noemie Ligot; Matthieu Pierre Rutgers; Laetitia Yperzeele; Filip Alexiev; Teodora Sakelarova; Marina Roje Bedeković; Hrvoje Budincevic; Igor Cindric; Zlatko Hucika; David Ozretic; Majda Seferovic Saric; František Pfeifer; Igor Karpowic; David Cernik; Martin Sramek; Miroslav Skoda; Helena Hlavacova; Lukas Klecka; Martin Koutny; Daniel Vaclavik; Ondrej Skoda; Jan Fiksa; Katerina Hanelova; Miroslava Nevsimalova; Robert Rezek; Petr Prochazka; Gabriela Krejstova; Jiri Neumann; Marta Vachova; Henryk Brzezanski; David Hlinovsky; Dusan Tenora; Rene Jura; Lubomír Jurák; Jan Novak; Ales Novak; Zdenek Topinka; Petr Fibrich; Helena Sobolova; Ondrej Volny; Hanne Krarup Christensen; Nicolas Drenck; Helle Klingenberg Iversen; Claus Z Simonsen; Thomas Clement Truelsen; Troels Wienecke; Riina Vibo; Katrin Gross-Paju; Toomas Toomsoo; Katrin Antsov; Francois Caparros; Charlotte Cordonnier; Maria Dan; Jean-Marc Faucheux; Laura Mechtouff; Omer Eker; Emilie Lesaine; Basile Ondze; Roxane Peres; Fernando Pico; Michel Piotin; Raoul Pop; Francois Rouanet; Tatuli Gubeladze; Mirza Khinikadze; Nino Lobjanidze; Alexander Tsiskaridze; Simon Nagel; Peter Arthur Ringleb; Michael Rosenkranz; Holger Schmidt; Annahita Sedghi; Timo Siepmann; Kristina Szabo; Götz Thomalla; Lina Palaiodimou; Dimitrios Sagris; Odysseas Kargiotis; Peter Klivenyi; Laszlo Szapary; Gabor Tarkanyi; Alessandro Adami; Fabio Bandini; Paolo Calabresi; Giovanni Frisullo; Leonardo Renieri; Davide Sangalli; Anne Pirson; Maarten Uyttenboogaart; Ido van den Wijngaard; Espen Saxhaug Kristoffersen; Waldemar Brola; Małgorzata Fudala; Ewa Horoch-Lyszczarek; Michal Karlinski; Radoslaw Kazmierski; Pawel Kram; Marcin Rogoziewicz; Rafal Kaczorowski; Piotr Luchowski; Halina Sienkiewicz-Jarosz; Piotr Sobolewski; Waldemar Fryze; Anna Wisniewska; Malgorzata Wiszniewska; Patricia Ferreira; Paulo Ferreira; Luisa Fonseca; João Pedro Marto; Teresa Pinho E Melo; Ana Paiva Nunes; Miguel Rodrigues; Vítor Tedim Cruz; Cristian Falup-Pecurariu; Georgi Krastev; Miroslav Mako; María Alonso de Leciñana; Juan F Arenillas; Oscar Ayo-Martin; Antonio Cruz Culebras; Exuperio Diez Tejedor; Joan Montaner; Soledad Pérez-Sánchez; Miguel Angel Tola Arribas; Alejandro Rodriguez Vasquez; Michael Mayza; Gianmarco Bernava; Alex Brehm; Paolo Machi; Urs Fischer; Jan Gralla; Patrik L Michel; Marios-Nikos Psychogios; Davide Strambo; Soma Banerjee; Kailash Krishnan; Joseph Kwan; Asif Butt; Luciana Catanese; Andrew M Demchuk; Thalia Field; Jennifer Haynes; Michael D Hill; Houman Khosravani; Ariane Mackey; Aleksandra Pikula; Gustavo Saposnik; Courtney Anne Scott; Ashkan Shoamanesh; Ashfaq Shuaib; Samuel Yip; Miguel A Barboza; Jose Domingo Barrientos; Ligia Ibeth Portillo Rivera; Fernando Gongora-Rivera; Nelson Novarro-Escudero; Anmylene Blanco; Michael Abraham; Diana Alsbrook; Dorothea Altschul; Anthony J Alvarado-Ortiz; Ivo Bach; Aamir Badruddin; Nobl Barazangi; Charmaine Brereton; Alicia Castonguay; Seemant Chaturvedi; Saqib A Chaudry; Hana Choe; Jae H Choi; Sushrut Dharmadhikari; Kinjal Desai; Thomas G Devlin; Vinodh T Doss; Randall Edgell; Mark Etherton; Mudassir Farooqui; Don Frei; Dheeraj Gandhi; Mikayel Grigoryan; Rishi Gupta; Ameer E Hassan; Johanna Helenius; Artem Kaliaev; Ritesh Kaushal; Priyank Khandelwal; Ayaz M Khawaja; Naim N Khoury; Benny S Kim; Dawn O Kleindorfer; Feliks Koyfman; Vivien H Lee; Lester Y Leung; Guillermo Linares; Italo Linfante; Helmi L Lutsep; Lisa Macdougall; Shailesh Male; Amer M Malik; Hesham Masoud; Molly McDermott; Brijesh P Mehta; Jiangyong Min; Manoj Mittal; Jane G Morris; Sumeet S Multani; Fadi Nahab; Krishna Nalleballe; Claude B Nguyen; Roberta Novakovic-White; Santiago Ortega-Gutierrez; Rahul H Rahangdale; Pankajavalli Ramakrishnan; Jose Rafael Romero; Natalia Rost; Aaron Rothstein; Sean Ruland; Ruchir Shah; Malveeka Sharma; Brian Silver; Marc Simmons; Abhishek Singh; Amy K Starosciak; Sheryl L Strasser; Viktor Szeder; Mohamed Teleb; Jenny P Tsai; Barbara Voetsch; Oscar Balaguera; Virginia A Pujol Lereis; Adriana Luraschi; Marcele Schettini Almeida; Fabricio Buchdid Cardoso; Adriana Conforto; Leonardo De Deus Silva; Luidia Varrone Giacomini; Fabricio Oliveira Lima; Alexandre L Longo; Pedro S C Magalhães; Rodrigo Targa Martins; Francisco Mont'alverne; Daissy Liliana Mora Cuervo; Leticia Costa Rebello; Lenise Valler; Viviane Flumignan Zetola; Pablo M Lavados; Victor Navia; Verónica V Olavarría; Juan Manuel Almeida Toro; Pablo Felipe Ricardo Amaya; Hernan Bayona; Angel Corredor; Carlos Eduardo Rivera Ordonez; Diana Katherine Mantilla Barbosa; Osvaldo Lara; Mauricio R Patiño; Luis Fernando Diaz Escobar; Donoband Edson Dejesus Melgarejo Fariña; Analia Cardozo Villamayor; Adolfo Javier Zelaya Zarza; Danny Moises Barrientos Iman; Liliana Rodriguez Kadota; Bruce Campbell; Graeme J Hankey; Casey Hair; Timothy Kleinig; Alice Ma; Rodrigo Tomazini Martins; Ramesh Sahathevan; Vincent Thijs; Daniel Salazar; Teddy Yuan-Hao Wu; Diogo C Haussen; David Liebeskind; Dileep R Yavagal; Tudor G Jovin; Osama O Zaidat; Thanh N Nguyen
Journal:  Neurology       Date:  2021-03-25       Impact factor: 11.800

4.  Effect of COVID-19 on Emergent Stroke Care: A Regional Experience.

Authors:  Jessica Hsiao; Emily Sayles; Eleni Antzoulatos; Robert J Stanton; Heidi Sucharew; Joseph P Broderick; Stacie L Demel; Matthew L Flaherty; Aaron W Grossman; Charles Kircher; Natalie Kreitzer; Katrina Peariso; Charles J Prestigiacomo; Peyman Shirani; Kyle B Walsh; Holly Lampton; Opeolu Adeoye; Pooja Khatri
Journal:  Stroke       Date:  2020-07-08       Impact factor: 7.914

5.  Impact of the Coronavirus Disease Pandemic on the Number of Strokes and Mechanical Thrombectomies: A Systematic Review and Meta-Analysis.

Authors:  Julius July; Raymond Pranata
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-07-22       Impact factor: 2.136

6.  Ischemic Stroke Epidemiology During the COVID-19 Pandemic: Navigating Uncharted Waters With Changing Tides.

Authors:  Georgios Tsivgoulis; Aristeidis H Katsanos; Raffaele Ornello; Simona Sacco
Journal:  Stroke       Date:  2020-06-04       Impact factor: 7.914

7.  Reduced Admissions for Cerebrovascular Events During COVID-19 Outbreak in Italy.

Authors:  Simona Sacco; Stefano Ricci; Raffaele Ornello; Paolo Eusebi; Luca Petraglia; Danilo Toni
Journal:  Stroke       Date:  2020-10-16       Impact factor: 7.914

8.  The impact of the COVID-19 pandemic on the care and management of patients with acute cardiovascular disease: a systematic review.

Authors:  Pauline Kiss; Cheryl Carcel; Carinna Hockham; Sanne A E Peters
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2021-01-25

9.  Impact of COVID-19 on stroke admissions, treatments, and outcomes at a comprehensive stroke centre in the United Kingdom.

Authors:  Nishita Padmanabhan; Indira Natarajan; Rachel Gunston; Marko Raseta; Christine Roffe
Journal:  Neurol Sci       Date:  2020-10-06       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.